secwatch.observer — SEC 8-K summary
======================================

Issuer:     Praxis Precision Medicines, Inc. (PRAX)
CIK:        0001689548
Form:       8-K
Filed at:   2024-01-10T23:59:59+00:00
Accession:  0001689548-24-000011
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 3.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Praxis licenses ulixacaltamide to Tenacia for Greater China; PRAX-628 Phase 2a PPR data positive; $81.3M cash
--------------------------------------------------------------------------------

- Entered exclusive collaboration with Tenacia Biotechnology for ulixacaltamide in essential tremor in Greater China.
- Issued 443,253 shares to BCPE (Bain Capital affiliate) at $22.5605/share (~20% premium) for $10M aggregate.
- Preliminary cash and equivalents as of Dec 31, 2023: $81.3 million.
- PRAX-628 Phase 2a PPR study: preliminary analysis of 15 mg cohort exceeded expectations; full data Q1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689548/000168954824000011/0001689548-24-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689548/000168954824000011/prax-20240104.htm
  HTML page:      https://secwatch.observer/filing/0001689548-24-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer